Vistagen Therapeutics (NASDAQ:VTGN) Trading 19.6% Higher
Shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) traded up 19.6% during trading on Monday . The stock traded as high as $0.63 and last traded at $0.61, 455,712 shares changed hands during mid-day trading. An increase of 48% from the average session volume of 308,048 shares. The stock had previously closed at $0.51.
Several analysts have commented on the stock. Chardan Capital reaffirmed a “neutral” rating on shares of Vistagen Therapeutics in a research report on Monday, July 29th. ValuEngine raised shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. Finally, Maxim Group set a $6.00 price objective on shares of Vistagen Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $3.55.
The firm’s 50-day moving average price is $0.59 and its 200-day moving average price is $0.94. The company has a debt-to-equity ratio of 2.44, a current ratio of 2.65 and a quick ratio of 2.65.
Vistagen Therapeutics Company Profile (NASDAQ:VTGN)
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Further Reading: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.